Ability Pharmaceuticals, SL has built an excellent research group composed by one postdoctoral research fellow, one Ph.D. student and one research technician, that perform all experimental procedures in cellular biology, molecular biology, proteomics and animal models for human cancers. The Lab is coordinated by Dr. Hector Perez-Montoyo, who is the Director of Biological Research of AbilityPharma. The Lab uses facilities of the Autonomous University of Barcelona (cell cultures, animal laboratory, cellular and genetic biology and biochemistry), in a collaboration established with Dr. José Miguel Lizcano, from the Department of Biochemistry and Molecular Biology at UAB.

The formation of the AbilityPharma Lab has allowed us to fully characterize the mechanism of action of ABTL0812, and to investigate new therapeutic scenarios for ABTL0812 and follow-ups. It has also facilitate the development of novel biomarkers and perform all pre-clinical studies needed to advance in the research pipeline of our compounds. On the clinical site, the Lab analyses the human patient samples from the clinical trial currently ongoing for the identification and validation of novel biomarkers to monitor and to predict efficacy, therefore allowing us to select the group of patients that will better respond to the treatment in future clinical studies, improving their success outcome.
 
Our Lab actively collaborates with other public institutions and research groups from different universities, research centers and hospitals (Vall d´Hebron-VHIO, Clinic Hospital-IDIBAPS, IRBLleida, UdG, Bellvitge Universitary Hospital), having built a network of expert scientists who by sharing their knowledge, expertise and results, have allowed AbilityPharma to optimize the efforts and resources to direct research to a common goal: “improve people´s life by providing novel cancer drugs”.